☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Immorna Biotherapeutics
Immorna Biotherapeutics Reports the US FDA’s IND Clearance to Commence P-I/II Trial of JCXH-211 IV for Solid Tumors
July 8, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.